ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Outsourcing Data Management: Challenges And Benefits

  Life sciences companies are grappling with a deluge of data. Yet strategic data management outsourcing offers potential benefits amidst regulatory and interoperability hurdles.

• Why Are Sponsor Organizations Using More Than 1 CTMS Solution?

  Explore evolutions in the eClinical market, CTMS use in the outsourcing community, and the difficulty in keeping up with requirements that sponsor organizations, CROs, and clinical trial sites experience regarding their CTMS solutions.

• AI In Clinical Trials: Key Insights From Industry Experts

  Find out what experts from the FDA are saying about AI’s ability to demonstrably impact three critical success metrics in clinical trials.

• Maximizing Clinical Data Insights With Advanced Analytics Platforms

  To achieve drug approval, trials must collect, combine, and analyze diverse data sets that support operational, safety review, risk management, and other analyses crucial to development.

• Five Steps To Streamline Your Trial

  Explore the solution for adequately verifying and analyzing data from wearables, remote devices, and other novel data collection modalities. 

• How Sponsors Can Leverage New Technologies To Lower Trial Costs

  This study introduces sponsors to an innovative, lean, and efficient approach to data management that integrates site-facing technologies to streamline trial operations.

• What The Joint FDA And EMA's AI Principles Can Mean For Clinical Trial Technology

  New FDA/EMA principles align global expectations for AI in drug trials, emphasizing transparency, human-centric design, and risk-based governance to ensure data integrity and patient safety.

• Medable's Japanese Clinical Trial Exceeds FPI Date And eCOA Adherence

  A top-10 global pharma company aimed to address eCOA adherence and patient enrollment challenges faced by clinical trial sites in Japan. Explore an initiative to enhance the patient and site experience.

• RBQM For Decentralized Trials: Two Key Areas Of Focus To Reduce Your Risk

  This article takes a more in-depth look at Sections 5.0.5: ‘Risk Communication’ and 5.0.6: ‘Risk Review.’ in ICH-GCP E6 R2 to show how the implementation of RBQM can reduce issues and achieve holistic trial oversight in today’s complex decentralized trials.

• Beyond The Pandemic: Why eCOAs Are Here To Stay

  The permanent adoption of eCOA is a natural step in the industry-wide effort to create a more patient-centric clinical trial experience. Learn more in the available blog.